Providers/Grant Support
This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical, the Obesity Medicine Association and RealCME.
This activity is supported by an education grant from Novo Nordisk.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
Orthopedic Surgeons
Program Overview
Obesity significantly impacts orthopedic health and surgical outcomes, with patients experiencing worse results following procedures such as total hip and knee arthroplasty. Weight loss interventions, including GLP-1 RAs, represent valuable tools for managing orthopedic patients with obesity. Historically, bariatric surgery was the primary weight loss option for morbidly obese patients before total joint arthroplasty, but GLP-1 RAs now offer an effective non-surgical alternative, with potential anti-inflammatory and disease-modifying effects for conditions like osteoarthritis.
Despite these benefits, significant knowledge and practice gaps exist among orthopedic specialists regarding GLP-1 RAs. While some orthopedists collaborate with obesity medicine specialists to help patients meet BMI cutoffs for surgery, many lack comprehensive understanding of these medications' mechanisms, benefits, and role in orthopedic care. Emerging research suggests GLP-1 drugs could substantially improve joint replacement outcomes, with ongoing studies exploring the role of semaglutide in spine lumbar fusions and other orthopedic surgeries. Knowledge and practice gaps among orthopedic specialists limit their ability to appropriately counsel patients and integrate these medications into comprehensive treatment plans.
Learning Objectives
After completing this activity, participants should be better able to:
- UNDERSTAND the clinical benefits of GLP-1 receptor agonists for obesity and its related comorbidities.
- IDENTIFY and MANAGE the adverse event profiles associated with GLP-1 receptor agonists using evidence-based strategies.
- DEVELOP patient-centered strategies to educate patients about the benefits, risks, and expectations of GLP-1 receptor agonist therapy.
- IMPLEMENT follow-up protocols to monitor patient progress, manage side effects, and improve adherence to GLP-1 receptor agonist therapy.
- DESCRIBE how GLP-1 receptor agonists align with orthopedic-specific care priorities, such as joint health.
- INDIVIDUALIZE counseling and management approaches for GLP-1 receptor agonist therapy to address orthopedic-specific patient needs, such as joint-related comorbidities.
Faculty
Carissa J. Tripi, DO
Medical Surgical Director
San Luis Valley Health - Alamosa, Colorado
Team Physician - Adams State University
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College of Thomas Jefferson University
Associate Director Family Medicine Residency Program
Jefferson Health - Abington
Jenkintown, PA
Tiffany N. Lowe Clayton, DO, FOMA, DABOM, MHPE
Vice-Chair, Dept. Family Medicine
Campbell University School of Osteopathic Medicine
Bariatrician WakeMed Bariatric Surgery
and Medical Weight Loss
Cary, North Carolina
Content Reviewer
Sara Velayati, MD, DABOM
Assistant Professor, Department of Medicine (Endocrinology)
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY
Planners
Steven Haimowitz, MD
RealCME
Erin Ash, MD
RealCME
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
Albert Einstein College of Medicine-Montefiore Medical Center designates this other/blended activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Credits
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Finanical Relationships
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.
Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.
All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.
*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosures
Carrissa J. Tripi, DO, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Neil Skolnik, MD, received honoraria for serving as a researcher, consultant, speaker, and advisory committee member for AstraZeneca; as a researcher, speaker, and advisory committee member for GlaxoSmithKline; as an advisory board member for Abbott; as a consultant and speaker for Heartland Food Group; for consulting services from Sanofi and Sanofi Pasteur; as a speaker and advisory committee member for Eli Lilly and Novo Nordisk; and as a speaker for Teva and Takeda. The financial relationship with Astellas has ended. The business lines and/or products of AstraZeneca, Eli Lilly and Heartland Food Group are relevant to the content of Dr. Skolnik’s presentation.
Tiffany N. Lowe Clayton, DO, DABOM, MHPE, received consultant fees for serving on the speakers’ bureaus of Novo Nordisk and Eli Lilly. The business lines and/or products of Novo Nordisk and Eli Lilly are relevant to the content of Dr. Clayton’s presentation.
Sara Velayati, MD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Steven Haimowitz, MD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Erin Ash, MD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME, and Takeda. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participation and Credit
Estimated time to complete this activity: 0.75 hours
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully answered all test questions, and have received a digital copy of your credit certificate.
If you are seeking credit, you must complete the post-test and evaluation at the conclusion of the activity.
Privacy Statement
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
Collect and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
Course Viewing Requirements
Contact Information
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at [email protected].
For technical questions related to this activity, please contact [email protected].